Neuronetics is a Malvern, PA based, publicly traded company incorporated in Delaware in April 2003,[4] that develops non-invasive treatments for psychiatric disorders that have shown resistance or lack of improvement using traditional medicine. The treatments are based upon neuromodulation technology.
 | |
| Company type | Public |
|---|---|
| Nasdaq: STIM Russell 2000 Index component | |
| Founded | 2003 |
| Headquarters | Malvern, PA, United States |
Key people | Keith J. Sullivan (President and CEO)[1][2] Stephen Furlong (CFO)[1]
Andrew Macan |
Number of employees | 167 As of March 31, 2018[update][4] |
| Website | neurostar |
Neuronetics became the "first and only Food and Drug Administration (FDA) approval for the clinical treatment of a specific form of medication-refractory depression using a TMS Therapy device (FDA approval K061053)."[5]
They manufacture a transcranial magnetic stimulation device, NeuroStar.[6] The NeuroStar TMS therapy is delivered via a precisely positioned magnetic coil against the patient's head.[7][8]
References
edit- ^ a b c "Neuronetics Announces the Appointment of Keith J. Sullivan as President and Chief Executive Officer" (Press release). Neuronetics. Retrieved July 15, 2020.
- ^ "Neuronetics names new CEO". Seeking Alpha. Retrieved July 15, 2020.
- ^ "NeuroStar Executive Team". Neuronetics.
- ^ a b "Neuronetics, Inc. (stim) IPO". NASDAQ.com.
- ^ Horvath, J. C.; Mathews, J.; Demitrack, M. A.; Pascual-Leone, A. (July 12, 2010). "The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression". Journal of Visualized Experiments (45): 2345. doi:10.3791/2345. PMC 3159591. PMID 21189465.
- ^ "Hello Health: How transcranial magnetic stimulation treats major depressive disorder". November 11, 2020.
- ^ "MercyOne TMS Therapy Des Moines, Iowa". YouTube. May 25, 2021.[dead YouTube link]
- ^ "Neuronetics' NeuroStar TMS device".
